Media Analytics Corp

  • TickerMEDA
  • ISINUS5843932014
  • ExchangePink OTC Markets
  • SectorFinancial Services
  • CountryUnited States
Eric Le Berrigaud

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

Dylan Van Haaften

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

Victor Floc’h

MEDARTIS BUY | CHF60 vs. CHF57 Leaving the Joint for the Extremity

1H20 offers solid foundation for things to come Medartis hits the right notes in regards to US Investors should elect Trauma over Elective surgery exposure Update post 1H20, FV to CHF60 vs CHF57, re-iterate Buy

Dylan Van Haaften

MEDARTIS: 1H19 beat highlights resilience in Extremities | BUY | CHF57(+49%)

MEDARTIS - BUY | CHF57(+49%) 1H19 beat highlights resilience in Extremities 1H19 beats +12% on revenue vs consensus Trauma surgery demand remains robust in spite of COVID Managing cost and FX likely to remain volatile in 2H19 Re-iterate Buy and FV CHF57

Victor Floc’h

MEDARTIS: Medartis’ strong focus on trauma will be key in this challenging environment | BUY | CHF57 vs. CHF64 (+46%)

MEDARTIS - BUY | CHF57 vs. CHF64 (+46%) Medartis’ strong focus on trauma will be key in this challenging environment 2020 guidance withdrawn due to global spread of Covid-19 Strong disruption in procedures, but traumatology is less affected Medartis should benefit from the resilience of trauma A well experienced executive to take over US business

Eric Le Berrigaud

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

Dylan Van Haaften

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

Victor Floc’h

MEDARTIS BUY | CHF60 vs. CHF57 Leaving the Joint for the Extremity

1H20 offers solid foundation for things to come Medartis hits the right notes in regards to US Investors should elect Trauma over Elective surgery exposure Update post 1H20, FV to CHF60 vs CHF57, re-iterate Buy

Dylan Van Haaften

MEDARTIS: 1H19 beat highlights resilience in Extremities | BUY | CHF57(+49%)

MEDARTIS - BUY | CHF57(+49%) 1H19 beat highlights resilience in Extremities 1H19 beats +12% on revenue vs consensus Trauma surgery demand remains robust in spite of COVID Managing cost and FX likely to remain volatile in 2H19 Re-iterate Buy and FV CHF57

Victor Floc’h

MEDARTIS: Medartis’ strong focus on trauma will be key in this challenging environment | BUY | CHF57 vs. CHF64 (+46%)

MEDARTIS - BUY | CHF57 vs. CHF64 (+46%) Medartis’ strong focus on trauma will be key in this challenging environment 2020 guidance withdrawn due to global spread of Covid-19 Strong disruption in procedures, but traumatology is less affected Medartis should benefit from the resilience of trauma A well experienced executive to take over US business

ResearchPool Subscriptions

Get the most out of your insights

Get in touch